Cyclin-Dependent Kinase 5 in Amyotrophic Lateral SclerosisNguyen M.D.a · Julien J.-P.b
aDepartment of Pathology, Harvard Medical School, Boston, Mass., USA; bCHUL Research Center, Laval University, Sainte-Foy, Que., Canada
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Amyotrophic lateral sclerosis is a neurological disorder that selectively affects motor neurons of brain and spinal cord. Emerging evidence indicates an involvement of the serine/threonine-cyclin-dependent kinase 5 (Cdk5) in the pathogenesis. Deregulation of Cdk5 by its truncated co-activators, p25 and p29, contributes to neurodegeneration by altering the phosphorylation state of cytosolic and cytoskeletal proteins and, possibly, through the induction of cell cycle regulators. The present paper reviews these findings and proposes new perspectives to decipher the mechanisms of neurodegeneration in amyotrophic lateral sclerosis induced by Cdk5.
© 2003 S. Karger AG, Basel
- Cleveland DW, Rothstein JD: From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806–819.
- Julien JP: Amyotrophic lateral sclerosis: Unfolding the toxicity of the misfolded. Cell 2001;104:581–591.
Robertson J, Kriz J, Nguyen MD, Julien JP: Pathways to motor neuron degeneration in transgenic mouse models. Biochimie 2002;84:1151–1160.
- Tannoch VJ, Hinds PW, Tsai LH: Cell cycle control. Adv Exp Med Biol 2000;465:127–140.
- Morgan DO: Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261–291.
- Dhavan R, Tsai LH: A decade of CDK5. Nat Rev Mol Cell Biol 2001;2:749–759.
- Nguyen MD, Mushynski WE, Julien JP: Cyclin at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 2002;9:1294–1306.
- Bajaj NP, Al-Sarraj ST, Anderson V, Kibble M, Leigh N, Miller CC: Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis. Neurosci Lett 1998;245:45–48.
- Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615–622.
- Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000;405:360–364.
- Patzke H, Tsai LH: Calpain-mediated cleavage of the cyclin-dependent kinase 5 activator p39 to p29. J Biol Chem 2002;277:8054–8060.
- Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S: Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 2000;275:17166–17172.
- Nath R, Davis M, Probert AW, Kupina NC, Ren X, Schielke GP, Wang KK: Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun 2000;274:16–21.
- Tseng HC, Zhou Y, Shen Y, Tsai LH: A survey of Cdk5 activator p35 and p25 levels in Alzheimer’s disease brains. FEBS Lett 2002;523:58–62.
- Nguyen MD, Larivière RC, Julien JP: Deregulation of Cdk5 in a mouse model of ALS: Toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001;30:135–147.
- Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD: Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 2000;97:2910–2915.
Bian F, Nath R, Sobocinski G, Booher RN, Lipinski WJ, Callahan MJ, Pack A, Wang KK, Walker LC: Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 2002;446:257–266.
- Humbert S, Dhavan R, Tsai L: p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J Cell Sci 2000;113:975–983.
- Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH: p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5), is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998;273:24057–24064.
Saito T, Onuki R, Fujita Y, Kusakawa G, Ishiguro K, Bibb JA, Kishimoto T, Hisanaga S: Developmental regulation of the proteolysis of the p35 cyclin-dependent kinase 5 activator by phosphorylation. J Neurosci 2003;23:1189–1197.
- Urushitani M, Kurisu J, Tsukita K, Takahashi R: Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem 2002:83:1030–1042.
- Patzke H, Tsai LH: Cdk5 sinks into ALS. Trends Neurosci 2002;25:8–10.
- Wang J, Xu G, Gonzales V, Coonfield M, Fromholt D, Copeland NG, Jenkins NA, Borchelt DR: Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol Dis 2002;10:128–138.
- Lefebvre S, Mushynski WE: Calcium binding to untreated and dephosphorylated porcine neurofilaments. Biochem Biophys Res Commun 1987;145:1006–1011.
- Lefebvre S, Mushynski WE: Characterization of the cation-binding properties of porcine neurofilaments. Biochemistry 1988;27:8503–8508.
- Okano HJ, Pfaff DW, Gibbs RB: RB and Cdc2 expression in brain: Correlations with 3H-thymidine incorporation and neurogenesis. J Neurosci 1993;13:2930–2938.
- Tsai LH, Takahashi T, Caviness VS Jr, Harlow E: Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 1993;119:1029–1040.
Carey RG, Li B, DiCicco-Bloom E: Pituitary adenylate cyclase activating polypeptide anti-mitogenic signaling in cerebral cortical progenitors is regulated by p57Kip2-dependent CDK2 activity. J Neurosci 2002;22:1583–1591.
- Liu DX, Greene LA: Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res 2001;305:217–228.
- Husseman JW, Nochlin D, Vincent I: Mitotic activation: A convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol Aging 2000;21:815–828.
- Park DS, Obeidat A, Giovanni A, Greene LA: Cell cycle regulators in neuronal death evoked by excitotoxic stress: Implications for neurodegeneration and its treatment. Neurobiol Aging 2000;21:771–781.
- Osuga H, Osuga S, Wang F, Fetni R, Hogan MJ, Slack RS, Hakim AM, Ikeda JE, Park DS: Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A 2000;97:10254–10259.
- Giovanni A, Keramaris E, Morris EJ, Hou ST, O’Hare M, Dyson N, Robertson GS, Slack RS, Park DS: E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3. J Biol Chem 2000;275:11553–11560.
- Liu DX, Greene LA: Regulation of neuronal survival and death by E2F-dependent gene repression and derepression. Neuron 2001;32:425–438.
- Ranganathan S, Scudiere S, Bowser R: Hyperphosphorylation of the retinoblastoma gene product and altered subcellular distribution of E2F-1 during Alzheimer’s disease and amyotrophic lateral sclerosis. J Alzheimers Dis 2001;3:377–385.
Ranganathan S, Bowser R: Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol 2003;162:823–835.
Nguyen MD, Boudreau M, Kriz J, Couillard-Despres S, Kaplan DR, Julien JP: Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci 2003;23:2131–2140.
- Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K: Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 2001;306:37–40.
- Kriz J, Nguyen MD, Julien JP: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268–278.
- Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74–78.
- Lee KY, Helbing CC, Choi KS, Johnston RN, Wang JH: Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. J Biol Chem 1997;272:5622–5626.
- Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, Gertler FB, Vidal M, Van Etten RA, Tsai LH: Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 2000;26:633–646.
- Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, Peters G: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 1994;9:71–79.
- Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J, Mao Z: Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 2003;38:33–46.
- Xiong W, Pestell R, Rosner MR: Role of cyclins in neuronal differentiation of immortalized hippocampal cells. Mol Cell Biol 1997;17:6585–6597.
- Zheng M, Leung CL, Liem RK: Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J Neurobiol 1998;35:141–159.
- Cai XH, Tomizawa K, Tang D, Lu YF, Moriwaki A, Tokuda M, Nagahata S, Hatase O, Matsui H: Changes in the expression of novel Cdk5 activator messenger RNA (p39nck5ai mRNA) during rat brain development. Neurosci Res 1997;28:355–360.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.